Jeannette Potts Sells 3,412 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

uniQure Price Performance

Shares of QURE stock opened at $14.27 on Friday. The company has a quick ratio of 7.12, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure N.V. has a 12-month low of $7.76 and a 12-month high of $71.50. The firm has a fifty day moving average of $22.04 and a 200-day moving average of $29.53. The firm has a market capitalization of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, equities research analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of QURE. Private Trust Co. NA acquired a new position in uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the third quarter valued at approximately $50,000. Torren Management LLC bought a new stake in shares of uniQure in the fourth quarter worth $28,000. Finally, FNY Investment Advisers LLC lifted its position in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on QURE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Tuesday, February 10th. Mizuho reissued a “neutral” rating and set a $12.00 price objective (down from $33.00) on shares of uniQure in a research report on Tuesday, March 3rd. Finally, Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a report on Tuesday. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure has an average rating of “Hold” and a consensus target price of $34.33.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo?controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back?and?forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class?action and shareholder?lawsuit notices filed and circulated by law firms (lead?plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell?side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single?digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short?term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT?130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.